US FDA Registration and Device Listing for NeuroStrip
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Control Bionics Ltd. has announced the completion of US FDA registration and device listing for its NeuroStrip wearable platform, establishing its status as a medical device in the US market. This registration is a significant milestone that enhances NeuroStrip's credibility and supports the company's broader regulatory strategy. The FDA listing will aid in commercial discussions and is expected to facilitate engagement with advanced clinical rehabilitation providers and medical research institutions. Control Bionics is also pursuing regulatory approvals in other key jurisdictions, including Australia and Europe.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Control Bionics
- Commercial momentum builds across both platform pillars
- Completion of Placement
- Pause in Trading
- Commercial Momentum Presentation
- German Statutory Reimbursement Listing for NeuroNode
Later from Control Bionics
- NeuroStrip secures MHRA registration
- Medicare Billing Code Secured for NextLevel Speech Devices
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Control Bionics into a list and get an email when it puts out news.
Follow Control Bionics